The newly established human hepatocyte cell line: application for the bioartificial liver

Harimoto, Norifumi; Taketomi, Akinobu; Kitagawa, Dai; Kuroda, Yasuhiro; Itoh, Shinji; Gion, Tomonobu; Tanaka, Shinji; Shirabe, Ken; Shimada, Mitsuo; Maehara, Yoshihiko

doi:10.1016/j.jhep.2004.11.038

Cited by 14 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to human primary hepatocytes, IHH and Huh7 cells secreted liver-specific proteins at 2-4 logs lower levels. However, it has been shown that the phenotype of hepatocytes is strongly dependent upon culture conditions [22][23][24][25]. Interestingly, IHH had the ability to repopulate the liver of transplanted immunodeficient mice and to secrete liver-specific proteins in serum for up to 6 months without tumor formation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes

Nguyen

Mai

Villiger

et al. 2005

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Noteworthy, a extracorporeal BAL based on C3A cells, a subclone of HepG2 cells, a demonstrated tumorigenic hepatoma cell line [21,29,30], passed clinical safety tests [27]. Nonetheless, HepG2 cells stably expressing HSV/TK, a safeguard already incorporated in our IHH, were recently engineered to increase their biosafety [22].…”

Section: Discussionmentioning

confidence: 99%

Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes

Nguyen

Mai

Villiger

et al. 2005

Journal of Hepatology

View full text Add to dashboard Cite

“…We opted to use human HepG2 cell line for their similar morphology to adult primary hepatocytes, their tendency to attach and their albumin-synthesizing capacity, although their ammonia detoxification and mixed function oxidase activities were very poor. 52 These cells also undergo cell division (which is not the case for primary hepatocytes) and therefore allowed us to assess the potential scaffolds for their ability to support increasing cell numbers. This has relevance to the future hope of being able to use stem cells or partially committed progenitor cells at scale-up to provide liver support systems.…”

Section: Discussionmentioning

confidence: 99%

Modifying three-dimensional scaffolds from novel nanocomposite materials using dissolvable porogen particles for use in liver tissue engineering

et al. 2012

View full text Add to dashboard Cite

Background:Although hepatocytes have a remarkable regenerative power, the rapidity of acute liver failure makes liver transplantation the only definitive treatment. Attempts to incorporate engineered three-dimensional liver tissue in bioartificial liver devices or in implantable tissue constructs, to treat or bridge patients to self-recovery, were met with many challenges, amongst which is to find suitable polymeric matrices. We studied the feasibility of utilising nanocomposite polymers in three-dimensional scaffolds for hepatocytes.Materials and methods:Hepatocytes (HepG2) were seeded on a flat sheet and in three-dimensional scaffolds made of a nanocomposite polymer (Polyhedral Oligomeric Silsesquioxane [POSS]-modified polycaprolactone urea urethane) alone as well as with porogen particles, i.e. glucose, sodium bicarbonate and sodium chloride. The scaffold architecture, cell attachment and morphology were studied with scanning electron microscopy, and we assessed cell viability and functionality.Results:Cell attachment to the scaffolds was demonstrated. The scaffold made with glucose particles as porogen showed a narrower range of pore size with higher porosity and better inter-pore communications and seemed to encourage near normal cell morphology. There was a steady increase of albumin secretion throughout the experiment while the control (monolayer cell culture) showed a steep decrease after day 7. At the end of the experiment, there was no significant difference in viability and functionality between the scaffolds and the control.Conclusion:In this initial study, porogen particles were used to modify the scaffolds produced from the novel polymer. Although there was no significance against the control in functionality and viability, the demonstrable attachment on scanning electron microscopy suggest potential roles for this polymer and in particular for scaffolds made with glucose particles in liver tissue engineering.

show abstract

“…Selden et al employed HepG2 cells in a fluidized bed BAL by encapsulating the cells [28] or spheroids [29] in alginate beads and successfully improved important hepatic parameters in ALF pigs. Although the albuminsynthesizing capacity of the HepG2 cell line is good, the ammonia detoxification and mixed function oxidase activities of HepG2 cells are much poorer than those of primary hepatocytes [30]. The C3A cell line is a subclone of the HepG2 cell line with a higher degree of differentiation and P450 enzyme activity.…”

Section: Tumor-derived Hepatocytesmentioning

confidence: 99%

Bioartificial livers: a review of their design and manufacture

Tuerxun¹,

He²,

Ibrahim³

et al. 2022

Biofabrication

View full text Add to dashboard Cite

Acute liver failure (ALF) is a rapidly progressive disease with high morbidity and mortality rates. Liver transplantation and artificial liver support systems, such as artificial livers (ALs) and bioartificial livers (BALs), are the two major therapies for ALF. Compared to ALs, BALs are composed of functional hepatocytes that provide essential liver functions, including detoxification, metabolite synthesis, and biotransformation. Furthermore, BALs can potentially provide effective support as a form of bridging therapy to liver transplantation or spontaneous recovery for patients with ALF. In this review, we systematically discussed the currently available state-of-the-art designs and manufacturing processes for BAL support systems. Specifically, we classified the cell sources and bioreactors that are applied in BALs, highlighted the advanced technologies of hepatocyte culturing and bioreactor fabrication, and discussed the current challenges and future trends in developing next generation BALs for large scale clinical applications.

show abstract

The newly established human hepatocyte cell line: application for the bioartificial liver

Cited by 14 publications

References 49 publications

Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes

Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes

Modifying three-dimensional scaffolds from novel nanocomposite materials using dissolvable porogen particles for use in liver tissue engineering

Bioartificial livers: a review of their design and manufacture

Contact Info

Product

Resources

About